<?xml version='1.0' encoding='utf-8'?>
<document id="30830975"><sentence text="Treatment of prolonged tacrolimus toxicity using phenytoin in a haemodialysis patient."><entity charOffset="23-33" id="DDI-PubMed.30830975.s1.e0" text="tacrolimus" /><entity charOffset="49-58" id="DDI-PubMed.30830975.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.30830975.s1.e0" e2="DDI-PubMed.30830975.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s1.e0" e2="DDI-PubMed.30830975.s1.e1" /></sentence><sentence text="Treatment of tacrolimus toxicity includes holding tacrolimus and supportive care"><entity charOffset="13-23" id="DDI-PubMed.30830975.s2.e0" text="tacrolimus" /><entity charOffset="50-60" id="DDI-PubMed.30830975.s2.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.30830975.s2.e0" e2="DDI-PubMed.30830975.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s2.e0" e2="DDI-PubMed.30830975.s2.e1" /></sentence><sentence text=" The objective is to describe considerations for pharmacologic induction of tacrolimus metabolism"><entity charOffset="76-86" id="DDI-PubMed.30830975.s3.e0" text="tacrolimus" /></sentence><sentence text="" /><sentence text="A 52-year-old male with a failed renal transplant on chronic haemodialysis developed tacrolimus toxicity due to a drug-drug interaction with darunavir/ritonavir"><entity charOffset="85-95" id="DDI-PubMed.30830975.s5.e0" text="tacrolimus" /><entity charOffset="141-150" id="DDI-PubMed.30830975.s5.e1" text="darunavir" /><entity charOffset="151-160" id="DDI-PubMed.30830975.s5.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30830975.s5.e0" e2="DDI-PubMed.30830975.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s5.e0" e2="DDI-PubMed.30830975.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30830975.s5.e0" e2="DDI-PubMed.30830975.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30830975.s5.e1" e2="DDI-PubMed.30830975.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30830975.s5.e1" e2="DDI-PubMed.30830975.s5.e2" /></sentence><sentence text=" Tacrolimus concentrations were &gt;60 ng/mL for 10 days despite holding tacrolimus and darunavir/ritonavir"><entity charOffset="70-80" id="DDI-PubMed.30830975.s6.e0" text="tacrolimus" /><entity charOffset="85-94" id="DDI-PubMed.30830975.s6.e1" text="darunavir" /><entity charOffset="95-104" id="DDI-PubMed.30830975.s6.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30830975.s6.e0" e2="DDI-PubMed.30830975.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s6.e0" e2="DDI-PubMed.30830975.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30830975.s6.e0" e2="DDI-PubMed.30830975.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30830975.s6.e1" e2="DDI-PubMed.30830975.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30830975.s6.e1" e2="DDI-PubMed.30830975.s6.e2" /></sentence><sentence text=" Development of encephalopathy prompted initiation of phenytoin to induce tacrolimus metabolism"><entity charOffset="54-63" id="DDI-PubMed.30830975.s7.e0" text="phenytoin" /><entity charOffset="74-84" id="DDI-PubMed.30830975.s7.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.30830975.s7.e0" e2="DDI-PubMed.30830975.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s7.e0" e2="DDI-PubMed.30830975.s7.e1" /></sentence><sentence text=" Tacrolimus concentration was &lt;2 ng/mL within 4 days and mental status normalized" /><sentence text="" /><sentence text="Phenytoin metabolic induction is a therapeutic option for prolonged tacrolimus toxicity"><entity charOffset="0-9" id="DDI-PubMed.30830975.s10.e0" text="Phenytoin" /><entity charOffset="68-78" id="DDI-PubMed.30830975.s10.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.30830975.s10.e0" e2="DDI-PubMed.30830975.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30830975.s10.e0" e2="DDI-PubMed.30830975.s10.e1" /></sentence><sentence text="" /></document>